SCHEMBL599045

SCHEMBL599045

CC=C1c2ccccc2-c2ccccc21

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 1/20 0.43
DRD4 P21917 1/20 0.43
CYP19A1 P11511 2/20 0.41
CYP11B2 P19099 2/20 0.41
MEN1 O00255 3/20 0.38
KMT2A Q03164 3/20 0.38
MAPT P10636 2/20 0.38
HTT P42858 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
MAPK1 P28482 2/20 0.38
KDM4E B2RXH2 1/20 0.38
CES2 O00748 1/20 0.38
APAF1 O14727 1/20 0.38
TERT O14746 1/20 0.38
NPC1 O15118 1/20 0.38
PLIN1 O60240 1/20 0.38
TDP2 O95551 1/20 0.38
S1PR4 O95977 1/20 0.38
LMNA P02545 1/20 0.38
PLA2G1B P04054 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7325069 0.78 LMNA (0.50) DRD2DRD4MEN1KMT2AMAPT
SCHEMBL18557051 0.77 MYC (0.40) DRD2DRD4SMN1; SMN2MAPK1NPC1
SCHEMBL23095433 0.76 MAPT (0.54) MEN1KMT2AMAPTHTTSMN1; SMN2
SCHEMBL10005481 0.76 MAPK1 (0.43) DRD2DRD4MEN1KMT2ASMN1; SMN2
SCHEMBL4558454 0.76 ALDH1A1 (0.44) DRD2MEN1KMT2AMAPTMAPK1
SCHEMBL8859036 0.76 CES1 (0.56) DRD2DRD4CYP19A1CYP11B2MEN1
SCHEMBL8676274 0.76 CYP19A1 (0.46) CYP19A1CYP11B2MEN1KMT2AMAPT
SCHEMBL19336216 0.75 MAPT (0.52) MEN1KMT2AMAPTHTTSMN1; SMN2
SCHEMBL8218246 0.75 TRPA1 (0.49) DRD2DRD4MAPTHTTSMN1; SMN2
SCHEMBL1104624 0.75 MAPT (0.58) MEN1KMT2AMAPTHTTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0400972-B1 Fluorescent degree of cure monitors MINNESOTA MINING & MFG (US) 1996-07-03 EP claimed
US-5182316-A Forming a UV-detectable fluorophore in a mixture of hydride containing silicone, unsaturated silicone, cationically sensitive compound and a latent dibenzofulvene MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1993-01-26 US claimed
US-5047444-A Hydrosilatable polysiloxanes, unsaturated compounds and a dibenzofulvene chromogen; coatings MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1991-09-10 US claimed
EP-0400972-A2 Fluorescent degree of cure monitors MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1990-12-05 EP claimed
US-20120074336-A1 LIGHT-DRIVEN ROTARY MOLECULAR MOTORS BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION, ON BEHALF OF THE (US) 2012-03-29 US disclosed
US-8114997-B2 N4-acylcytosine nucleosides for treatment of viral infections PHARMASSET, INC. (US) 2012-02-14 US disclosed
US-7964722-B2 Light-driven rotary molecular motors BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION, ON BEHALF OF THE UNIVERSITY OF NEVADA, RENO (US) 2011-06-21 US disclosed
US-20110077394-A1 LIGHT-DRIVEN ROTARY MOLECULAR MOTORS NATIONAL SCIENCE FOUNDATION 2011-03-31 US disclosed
US-RE42015-E1 N4-acylcytosine-1,3-dioxolane nucleosides for treatment of viral infections PHARMASSET, INC. (US) 2010-12-28 US disclosed
EP-2091094-A2 Organic light-emitting element Yamagata Promotional Organization for Industrial Technology (JP) 2009-08-19 EP disclosed
US-20090176730-A1 N4-ACYLCYTOSINE NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS PHARMASSET, INC. (US) 2009-07-09 US disclosed
EP-1569652-A4 N SP 4 /SP-ACYLCYTOSINE NUCLEOSIDES FOR TREATMENT OF VIRAL IINFECTIONS PHARMASSET INC (US) 2008-07-02 EP disclosed
EP-0642483-A4 CHLORINATION AND ELIMINATION PROCESS AND SOME PRODUCTS THEREOF. 1995-04-19 EP disclosed
EP-0642483-A1 CHLORINATION AND ELIMINATION PROCESS AND SOME PRODUCTS THEREOF THE DOW CHEMICAL COMPANY (US) 1995-03-15 EP disclosed
US-5227560-A Vinylene or exomethylene groups from active methine compounds THE DOW CHEMICAL COMPANY (US) 1993-07-13 US disclosed
WO-1993009078-A1 CHLORINATION AND ELIMINATION PROCESS AND SOME PRODUCTS THEREOF THE DOW CHEMICAL COMPANY (US) 1993-05-13 WO disclosed
US-5182316-A Forming a UV-detectable fluorophore in a mixture of hydride containing silicone, unsaturated silicone, cationically sensitive compound and a latent dibenzofulvene MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1993-01-26 US disclosed
US-5118559-A Dibenzofulvene compound MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1992-06-02 US disclosed
US-5047444-A Hydrosilatable polysiloxanes, unsaturated compounds and a dibenzofulvene chromogen; coatings MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1991-09-10 US disclosed
EP-0400972-A2 Fluorescent degree of cure monitors MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1990-12-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090176730-A1 N4-ACYLCYTOSINE NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS ENTPD5, NT5C3B, PNP DRD2 1250/4885DRD4 440/4885CYP19A1 3276/4885
US-20110077394-A1 LIGHT-DRIVEN ROTARY MOLECULAR MOTORS CCNA2, CCNO, SCO2 DRD2 1087/4885DRD4 1823/4885CYP19A1 3455/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.